Mona Atta

Mona Atta

Auto-generated profile, based on publicly available information

Mona Atta

Department of Internal Medicine, Indiana University School of Medicine-Muncie, Muncie, IN 47306, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Hematology Reports
Verified
Journal Article
Open access
PDF file
AMAuthors: Sasmith R Menakuru
Authors: Sasmith R Menakuru
MAMona Atta
Mona Atta
VDVijaypal S. Dhillon
Vijaypal S. Dhillon
ASAhmed Salih
Ahmed Salih
Androgen usage has widely increased in recent times via prescribed and unprescribed means. Testosterone is a popular androgen taken by both athletes and the general population. While there is some evidence of androgens being thrombogenic, we report on a 19-year-old male who presented to the hospital after the usage of testosterone for one month, leading to the development of multiple pulmonary emboli and deep vein thrombosis. The authors hope to elucidate the relationship between testosterone usage and thrombosis formation.

24 May 2023 in Hematology Reports
Verified
Journal Article
Open access
PDF file
AMAuthors: Sasmith R Menakuru
Authors: Sasmith R Menakuru
VDVijaypal S. Dhillon
Vijaypal S. Dhillon
MAMona Atta
Mona Atta
KMKeeret Mann
Keeret Mann
ASAhmed Salih
Ahmed Salih
Methemoglobinemia is an acute medical emergency that requires prompt correction. Physicians should have a high degree of suspicion of methemoglobinemia in cases that present with hypoxemia that does not resolve with supplemental oxygenation, and they should confirm this suspicion with a positive methemoglobin concentration on arterial blood gas. There are multiple medications that can induce methemoglobinemia, such as local anesthetics, antimalarials, and dapsone. Phenazopyridine is an azo dye used over-the-counter as a urinary analgesic for women with urinary tract infections, and it has also been implicated in causing methemoglobinemia. The preferred treatment of methemoglobinemia is methylene blue, but its use is contraindicated for patients with glucose-6-phosphatase deficiency or those who take serotonergic drugs. Alternative treatments include high-dose ascorbic acid, exchange transfusion therapy, and hyperbaric oxygenation. The authors report a case of a 39-year-old female who took phenazopyridine for 2 weeks to treat dysuria from a urinary tract infection and subsequently developed methemoglobinemia. The patient had contraindications for the use of methylene blue and was therefore treated with high-dose ascorbic acid. The authors hope that this interesting case promotes further research into the utilization of high-dose ascorbic acid for managing methemoglobinemia in patients who are unable to receive methylene blue.